Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Meta-Analysis

Diammonium Glycyrrhizinate Preparation for Liver Function Recovery in Chronic Hepatitis B in China: A Meta-analysis with Trial Sequential Analysis

Author(s): Yibo Liu, Wenfang Guo and Minhui Li*

Volume 28, Issue 25, 2022

Published on: 28 July, 2022

Page: [2089 - 2112] Pages: 24

DOI: 10.2174/1381612828666220421134910

Price: $65

Abstract

Background: The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings. The use of the plant extract diammonium glycyrrhizinate (DG) in food and medicine has gradually widened because of its safety and effectiveness. DG is mainly used for liver-disease treatment in clinical practice, but DG intervention for CHB lacks systematic evidence.

Methods: The included randomized controlled trials were analyzed by comparator and control respectively for alanine aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TBIL) levels, hepatitis B virus DNA negative conversion ratio, and total effective rate, and subgroup analysis was conducted for intervention time, intervention dosage form, comparator drug, and combination drug, among others. Trial sequential analysis was used to verify the results.

Result: DG could effectively reduce ALT, AST, TBIL, and other liver-function indexes and had a definite effect on liver-function recovery. From the beginning of the intervention to 3 months, the effect was significantly better than that of conventional treatment. Compared with other drugs, different dosage forms had differences in efficacy, and DG enteric-coated capsules and injections were lower than compound glycyrrhizin and magnesium isoglycyrrhizin. Meanwhile, DG capsules had no significant difference from them. Meanwhile, trial sequential analysis of the main results confirmed the reliability of the conclusion.

Conclusion: To our knowledge, this was the first relatively complete meta-analysis and systematic evaluation of the efficacy of DG intervention for CHB; liver-function recovery was discussed in the context of traditional Chinese medicine thinking, and DG’s therapeutic effect on CHB was defined.

Keywords: Diammonium glycyrrhizinate, chronic hepatitis B, meta-analysis, TCM, TSA, ALT.

« Previous Next »
[1]
Chan SL, Wong VW, Qin S, Chan HL. Infection and cancer: The case of hepatitis B. J Clin Oncol 2016; 34(1): 83-90.
[http://dx.doi.org/10.1200/JCO.2015.61.5724] [PMID: 26578611]
[2]
Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011; 378(9791): 571-83.
[http://dx.doi.org/10.1016/S0140-6736(11)61097-0] [PMID: 21802134]
[3]
Noordeen F. Hepatitis B virus infection: An insight into infection outcomes and recent treatment options. Virusdisease 2015; 26(1-2): 1-8.
[http://dx.doi.org/10.1007/s13337-015-0247-y] [PMID: 26436115]
[4]
Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: A systematic review of data published between 1965 and 2013. Lancet 2015; 386(10003): 1546-55.
[http://dx.doi.org/10.1016/S0140-6736(15)61412-X] [PMID: 26231459]
[5]
Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30(12): 2212-9.
[http://dx.doi.org/10.1016/j.vaccine.2011.12.116] [PMID: 22273662]
[6]
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: The update. Int J Mol Sci 2016; 17(1): 14.
[http://dx.doi.org/10.3390/ijms17010014] [PMID: 26712744]
[7]
Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol 2021; 27(8): 666-76.
[http://dx.doi.org/10.3748/wjg.v27.i8.666] [PMID: 33716446]
[8]
Gao XL, Guo WY, Wu XM. Processing technology of licorice-whole wheat cake. Cereals & Oils 2017; 30(9): 18-21.
[http://dx.doi.org/10.3969/j.issn.1008-9578.2017.09.005]
[9]
Wang MS. Development of licorice mung bean cake. Acad Period Farm Prod Proc 2019; 479(09): 19-20.
[10]
Sun J, Zhuang Y, Hu F, Yang Y. Research progress of glycyrrhizin sweetener %. J China Food Additives 2020; 31(11): 144-8.
[http://dx.doi.org/10.19804/j.issn1006-2513.2020.11.021]
[11]
Shi HJ, Song HB, Wang L, Xiao SX, Bo KP, Ma W. The synergy of diammonium glycyrrhizinate remarkably reduces the toxicity of oxymatrine in ICR mice. Biomed Pharmacother 2018; 97: 19-25.
[http://dx.doi.org/10.1016/j.biopha.2017.09.039] [PMID: 29080454]
[12]
Zhu X, Chen C, Ye D, et al. Diammonium glycyrrhizinate upregulates PGC-1α and protects against Aβ1-42-induced neurotoxicity. PLoS One 2012; 7(4): e35823.
[http://dx.doi.org/10.1371/journal.pone.0035823] [PMID: 22540007]
[13]
Jin J, Xiong T, Hou X, et al. Role of Nrf2 activation and NF-κB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice. Food Chem Toxicol 2014; 73: 95-104.
[http://dx.doi.org/10.1016/j.fct.2014.08.009] [PMID: 25152329]
[14]
Zhang S. Effects of entecavir combined with diammonium glycyrrhizinate on liver fibrosis and liver function in patients with chronic viral hepatitis B. Med Innov China 2020; 17(24): 131-4.
[http://dx.doi.org/10.3969/j.issn.1674-4985.2020.24.033]
[15]
Wang T. Clinical efficacy of entecavir combined with liver protection in the treatment of viral active chronic hepatitis B. Home Med 2020; (8): 152-3.
[16]
Wang HZ. Effect of diammonium glycyrrhizinate enteric-coated capsules combined with entecavir on hepatitis B cirrhosis. China Cont Med Edu 2020; 12(29): 134-7.
[http://dx.doi.org/10.3969/j.issn.1674-9308.2020.29.039]
[17]
Sun CJ. Effect observation and effectiveness analysis of magnesium isoglycyrrhizinate in treatment of chronic hepatitis B. Sichuan J Anat 2020; 28(3): 161-2.
[http://dx.doi.org/10.3969/j.issn.1005-1457.2020.03.077]
[18]
Liu YP. Clinical observation of diammonium glycyrrhizinate capsule in the treatment of 46 children with chronic hepatitis B liver fibrosis. Zhongguo Fuyou Baojian 2009; 24(30): 4316-7.
[19]
Na L. Clinical effect of entecavir combined with diammonium glycyrrhizinate in the treatment of chronic viral hepatitis B. Acta Acad Med Guangxi 2018; 35(1): 75-7.
[http://dx.doi.org/10.16190/j.cnki.45-1211/r.2018.01.020]
[20]
Yan SJ. Effect of magnesium isoglycyrrhizinate injection on chronic hepatitis B. J Health Care Today 2018; 12: 100-1.
[21]
Wu WZ. The effect of diammonium glycyrrhizinate injection combined with tiopronin on serum levels of ALT,TBIL, ALB, and quality of life in patients with chronic hepatitis B. Int Med Health Guidance News 2018; 24(1): 85-9.
[http://dx.doi.org/10.3760/cma.j.issn.1007-1245.2018.01.027]
[22]
Lu ZQ. Clinical analysis of compound glycyrrhizin in the treatment of chronic hepatitis B. Guide of Chin Med 2018; 16(6): 125-6.
[23]
Li YH. Effect of magnesium isoglycyrrhizinate in the clinical treatment of chronic hepatitis B. Mod Diagnosis Treatment 2018; 29(11): 1733-4.
[http://dx.doi.org/10.3969/j.issn.1001-8174.2018.11.029]
[24]
Yang FT. To observe the effect of magnesium isoglycyrrhizinate injection in the treatment of chronic hepatitis B. Health Guide 2017; (24): 325.
[25]
Lu C. Research on clinical feasibility of compound glycyrrhizin in treatment of chronic hepatitis B. Chin Foreign Med Treat 2017; 36(6): 123-4.
[http://dx.doi.org/10.16662/j.cnki.1674-0742.2017.06.123]
[26]
Gao XY. Clinical observation of Shuilinjia capsule combined with tiopronin in treating 60 cases of chronic hepatitis B. Guide of China Med 2017; 15(09): 193.
[27]
Chen SD. Efficacy of CHSGS combined with interferon-α against chronic hepatitis B and effects on serum TNF-α, IL-6. Zhongguo Yiyuan Yaoxue Zazhi 2017; 37(17): 1716-20.
[http://dx.doi.org/10.13286/j.cnki.chinhosppharmacyj.2017.17.14]
[28]
Zhang JJ. Observation of magnesium isoglycyrrhizinate injection in treatment of chronic hepatitis B. China Prac Med 2016; 11(24): 111-2.
[http://dx.doi.org/10.14163/j.cnki.11-5547/r.2016.24.083]
[29]
Chen JX. Effect of magnesium isoglycyrrhizinate injection on chronic hepatitis B. J Clin Med Liter 2016; 3(56): 11199-202.
[30]
Wen J. Clinical effect analysis of compound glycyrrhizin in treatment of 128 cases of chronic viral hepatitis B. Chin Pract Med 2015; 10(36): 129-30.
[http://dx.doi.org/10.14163/j.cnki.11-5547/r.2015.36.092]
[31]
Peng FJ. Clinical experience of diammonium glycyrrhizinate capsule combined with tebivudine in the treatment of 30 cases of chronic viral hepatitis B. China J Pharm Econ 2014; 9(3): 79-80.
[32]
Huang W. Effect comparison of magnesium isoglycyrrhizinate and diammonium glycyrrhizinate in the treatment of chronic hepatitis B. Med Infant 2014; (11): 490-1.
[http://dx.doi.org/10.3969/j.issn.1006-1959.2014.11.610]
[33]
Zhang QE. Clinical observation on liver-nourishing enzyme-declining mixture for 40 cases of chronic hepatitis B. J Tradit Chin Med 2014; 55(22): 1929-32.
[http://dx.doi.org/10.13288/j.11-2166/r.2014.22.012]
[34]
Chang QY. Efficacy of diammonium glycyrrhizinate injection combined with Shengmai injection in the treatment of chronic hepatitis B. Zhongguo Xiandai Yaowu Yingyong 2014; 8(1): 3-4.
[35]
Ma NN. Clinical study of Baogan Fugong Pill in the treatment of chronic viral hepatitis B Hubei University of Traditional Chinese Medicine. 2013. Available from https://kns.cnki.net/kcms/detail/detail.aspx?FileName=1013208559.nh&DbName=CMFD2013
[36]
Li XC. Therapeutic effect of compound glycyrrhizin on 56 cases of chronic viral hepatitis B. J China Health Care Nut 2013; (10): 5908.
[37]
Zhang YL. Clinical observation of magnesium isoglycyrrhizinate and diamine glycyrrhizinate in the treatment of chronic severe hepatitis B% J Inner Mongol. J Tradit Chin Med 2012; 31(07): 54-5.
[http://dx.doi.org/10.3969/j.issn.1006-0979.2012.07.062]
[38]
Ye P. Clinical research on treatment on chronic liver hepatitis with magnesium isoglycurrhizinate. Chin Pract Med 2012; 7(11): 51-2.
[http://dx.doi.org/10.3969/j.issn.1673-7555.2012.11.025]
[39]
Wang XJ. Clinical evaluation of compound glycyrrhizin in the treatment of chronic hepatitis B. J Aesthet Med 2012; 21(14): 317-8.
[http://dx.doi.org/10.3969/j.issn.1008-6455.2012.14.229]
[40]
Shen QF. Comparison of therapeutic effects of different glycyrrhizins on chronic hepatitis B %J STRAIT. Pharm J 2012; 24(07): 101-3.
[http://dx.doi.org/10.3969/j.issn.1006-3765.2012.07.046]
[41]
Zhang M. Observation of curative effect of tanshinone II sodium A sulfonate combined with compound glycyrrhizin in treatment of chronic hepatitis B. Int Med Health Guidance News 2012; (18): 2711-3.
[http://dx.doi.org/10.3760/cma.j.issn.1007-1245.2012.18.024]
[42]
Wang YP. Clinical study on the treatment of chronic viral hepatitis b by JiangMei pill. Shandong: Shandong University of Traditional Chinese Medicine 2012.
[http://dx.doi.org/10.7666/d.D460341]
[43]
Zhang XH. 68 cases of chronic hepatitis b treated by jiangmei decoction. Henan Trad Chinese Med 2011; 31(12): 1387-8.
[44]
Xu QJ. Efficacy analysis of atomolan in the treatment of chronic hepatitis B. Chinese Commun Doctors 2011; 13(14): 64.
[http://dx.doi.org/10.3969/j.issn.1007-614x.2011.14.059]
[45]
Shi C. Effect of compound biie jia rangan tablet combined with lamivudine on hepatic fibrosis of chronic hepatitis B. J Chengde Med College 2011; 28(03): 270-1.
[http://dx.doi.org/10.3969/j.issn.1004-6879.2011.03.018]
[46]
Guo XY. Compound glycyrrhizin injection combined with Fuzheng huayu capsule in the treatment of 100 cases of chronic hepatitis B liver fibrosis. Mod J Integ Trad Chinese Western Med 2011; 20(32): 4083-4.
[http://dx.doi.org/10.3969/j.issn.1008-8849.2011.32.018]
[47]
Zhao HY. Clinical analysis of 50 cases of chronic hepatitis B treated with compound glycyrrhizin. Chinese Foreign Med Res 2011; 09(16): 36-7.
[http://dx.doi.org/10.3969/j.issn.1674-6805.2011.16.021]
[48]
Liu JP. Clinical observation of magnesium isoglycyrrhizinate in the treatment of chronic hepatitis B. J Clin Med 2011; 15(5): 81-2.
[http://dx.doi.org/10.3969/j.issn.1672-2353.2011.05.030]
[49]
Zhang CZ. Comparison of therapeutic effects of different glycyrrhizins on chronic hepatitis B. China Pharmaceut 2010; 19(11): 83.
[http://dx.doi.org/10.3969/j.issn.1006-4931.2010.11.061]
[50]
Zheng YL. Clinical observation of diammonium glycyrrhizinate in the treatment of chronic hepatitis B. J Tradit Chin Med 2010; 2(17): 207-8.
[51]
Gui YP. Effect of magnesium isoglycyrrhizinate on chronic hepatitis B. Guide China Med 2010; 8(36): 76-7.
[http://dx.doi.org/10.15912/j.cnki.gocm.2010.36.134]
[52]
Zhang T. Effect of compound Salvia miltiorrhiza combined with diammonium glycyrrhizinate on hepatic fibrosis with chronic hepatitis B. J Tradit Chin Med 2010; 24(01): 64-5.
[http://dx.doi.org/10.3969/j.issn.1671-7813.2010.01.34]
[53]
Shao G. Treatment of 360 cases of chronic hepatitis B with self-prepared hepatitis B I tablet. Proc Clin Med 2010; 19(16): 1080.
[54]
Lou D. Benefit evaluation of matrine injection and diammonium glycyrrhizinate injection in treatment of chronic hepatitis. China Mod Med 2010; 17(11): 114-5.
[http://dx.doi.org/10.3969/j.issn.1674-4721.2010.11.076]
[55]
Xiao H. The efficacy of Xize Tang in treatment of patients with chronic hepatitis B. J. Clin Exp Med 2009; 8(11): 50-3.
[http://dx.doi.org/10.3969/j.issn.1671-4695.2009.11.025]
[56]
Hu ZB. Clinical observation on the treatment of chronic hepatitis B with liver fibrosis by dangfiliganing capsule. Mod J Integr Tradit Chin West Med 2009; 18(23): 2801-2.
[http://dx.doi.org/10.3969/j.issn.1008-8849.2009.23.031]
[57]
Chen Y. Shugan yipi keli treatment of 70 cases of chronic hepatitis B. J Tradit Chin Med 2009; 23(09): 45-6.
[http://dx.doi.org/10.3969/j.issn.1671-7813.2009.09.24]
[58]
Chen RL. Evaluation of efficacy of glutathione combined with ademetionine in treatment of hepatitis B patients. China Trop Med 2009; 9(09): 1686-7.
[59]
Zhang JS. Clinical observation of compound glycyrrhizin combined with adefovir dipivoxil in the treatment of chronic hepatitis B. Zhongguo Xiandai Yaowu Yingyong 2009; 3(19): 82-3.
[http://dx.doi.org/10.3969/j.issn.1673-9523.2009.19.067]
[60]
Yang JY. Effect analysis of stronger Neo-minophagen C in treatment of chronic hepatitis B. Chin J Clin Rational Drug Use 2009; 2(15): 15-6.
[http://dx.doi.org/10.3969/j.issn.1674-3296.2009.15.007]
[61]
Hu J. Therapeutic effect of magnesium isoglyeyrrhizinate on chronic hepatitis B. Med J West China 2009; 21(4): 636-9.
[http://dx.doi.org/10.3969/j.issn.1672-3511.2009.04.048]
[62]
Chen YJ. Effect analysis of magnesium isoglycyrrhizinate in the treatment of chronic hepatitis B. J China. Pract Med 2009; 4: 168.
[http://dx.doi.org/10.3969/j.issn.1673-7555.2009.04.128]
[63]
Chen LY. Effect of magnesium isoglycyrrhizinate combined with Xinganbao capsule on chronic hepatitis B. Proc Clin Med 2009; 18(06): 130.
[64]
Wang GQ. XG F. Effect of ganlicin injection on hepatic fibrosis indexes of chronic hepatitis B. Chin Clin Pract Med 2009; (11): 93-4.
[http://dx.doi.org/10.3760/cma.j.issn1673-8799.2009.11.60]
[65]
Zhang Q, Interferon-α LS. 2b and thymosin combined with diammonium glycyrrhizinate for chronic hepatitis B. Med J Qilu 2009; 24(1): 23-5.
[http://dx.doi.org/10.3969/j.issn.1008-0341.2009.01.011]
[66]
Li YJ. Clinical efficacy of tiopronin on chronic hepatitis B. Xiandai Shengwu Yixue Jinzhan 2009; 9(15): 2869-71.
[67]
Gu XF. Early curative effect of tianqingganping combined with tebivudine in the treatment of chronic hepatitis B. Med Infant 2008; (11): 2060-1.
[http://dx.doi.org/10.3969/j.issn.1006-1959.2008.11.057]
[68]
Zhou LW. Clinical effects and immunomodulatory roles of atomolam in treatment of chronic hepatitis B. Med Recapitulate 2008; (19): 3034-5.
[http://dx.doi.org/10.3969/j.issn.1006-2084.2008.19.056]
[69]
Zhang B. Compound glycyrrhizin combined with injectio salviae miltiorrhizae composita in the treatment of chronic type B hepatitis. Chin J Pract Med 2008; 35(19): 7-8.
[http://dx.doi.org/10.3760/cma.j.issn.1674-4756.2008.19.004]
[70]
Wang Y. Therapeutic efficacy of matrine and diammonium glyeyrrihizinate on chronic hepatitis B. Chin Clin Pract Med 2008; 2(9): 30-2.
[71]
Liu MJ. Clinical observation of diamine glycyrrhizinate in the treatment of chronic hepatitis b 78. J Pract Med Techniques 2008; 27: 3715-6.
[http://dx.doi.org/10.3969/j.issn.1671-5098.2008.27.050]
[72]
Zhao FP. Clinical observe on Wuling pill in treating chronic hepatitis B. J Trop Dis 2007; (2): 102-3.
[http://dx.doi.org/10.3969/j.issn.1672-2302.2007.02.011]
[73]
Xu LC. Clinical application of hepatocellular growth hormone in the treatment of chronic hepatitis B. Med J West China 2007; (1): 50-1.
[http://dx.doi.org/10.3969/j.issn.1672-3511.2007.01.026]
[74]
Luo W. Observation on therapeutic effects of compound glycyrrhizin in the treatment of chronic viral hepatitis B. Pract J Med Pharm 2007; (9): 1030-1.
[http://dx.doi.org/10.3969/j.issn.1671-4008.2007.09.004]
[75]
Liu XL. Efficacy of stronger ner-minophagen C in treatment of chronic hepatitis B. Med J Chinese People’s Armed Police Forces 2007; (08): 574-7.
[http://dx.doi.org/10.3969/j.issn.1004-3594.2007.08.004]
[76]
Liu SW. Ganlixin joint kurarinone the treatment of chronic hepatitis B. Int Med Health Guidance News 2007; (11): 80-1.
[http://dx.doi.org/10.3760/cma.j.issn.1007-1245.2007.11.033]
[77]
Wang SP. Clinical analysis of lamivudine combined with garlicin in the treatment of chronic hepatitis B. Hebei Med J 2007; (07): 692-3.
[http://dx.doi.org/10.3969/j.issn.1002-7386.2007.07.022]
[78]
Xu QT. Clinical observation of magnesium isoglycyrrhizinate in the treatment of chronic hepatitis B. Chin J Clinical Hepatology 2007; 23(4): 282-3.
[http://dx.doi.org/10.3969/j.issn.1001-5256.2007.04.018]
[79]
Lei Y. Clinical research that three kinds of Glycyrrhizin to chronic B liver sufferer’s blood sugar and liver function viruses affect. J Dalian University 2006; 27(4): 35-8.
[http://dx.doi.org/10.3969/j.issn.1008-2395.2006.04.009]
[80]
Jiang H. Therapeutic effect of tianqingganping on 69 cases of chronic hepatitis b. Xiandai Yiyao Weisheng 2006.
[http://dx.doi.org/10.3969/j.issn.1009-5519.2006.13.040]
[81]
Chen Y. Efficacy and safety of diammonium glycyrrhizinate phosphatidylcholine complex in adults with chronic hepatitis B. Zhongguo Xin Yao Zazhi 2006; 15(1): 53-5.
[http://dx.doi.org/10.3321/j.issn:1003-3734.2006.01.015]
[82]
Yang HZ. Therapeutic effects of glycyrrhizin on chronic hepatitis B. Infect Dis Inform 2006; (03): 149-50.
[http://dx.doi.org/10.3969/j.issn.1007-8134.2006.03.023]
[83]
Zhuang KZ. Magnesium isoglycyrrhizinate combined with Yinzhihuang in the treatment of 40 cases of chronic viral hepatitis B. China Pharm 2009; 18(7): 58.
[http://dx.doi.org/10.3969/j.issn.1006-4931.2009.07.041]
[84]
Liu QR. Observation on the curative effect of Ganle in treating chronic hepatitis B. China Med 2006; 1: 35-6.
[http://dx.doi.org/10.3760/cma.j.issn.1673-4777.2006.01.017]
[85]
Wu C. Effect of matrine combined with compound Salvia miltiorrhiza on liver fibrosis in chronic hepatitis B. J. Pract Med 2006; (13): 1567-8.
[http://dx.doi.org/10.3969/j.issn.1006-5725.2006.13.047]
[86]
Wang Y. Clinical observation on the treatment of chronic hepatitis B by the combination of meineng and prostaglandin E-1. Zhongguo Yiyuan Yongyao Pingjia Yu Fenxi 2006; (5): 299-300.
[http://dx.doi.org/10.14009/j.issn.1672-2124.2006.05.015]
[87]
Huang C. Observation on curative effects of rhubarb combined with diammonium glycyrrhizinate treating chronic hepatitis B. Chin Gen Pract 2006; 9(20)
[http://dx.doi.org/10.3969/j.issn.1007-9572.2006.20.036]
[88]
Wang CX. Effect of atomolam combined with danshen on alteration markers of liver fibrosis in treatment of patients with chronic hepatitis B. J Xinjiang Medical Univ 2005; (6): 535-7.
[http://dx.doi.org/10.3969/j.issn.1009-5551.2005.06.015]
[89]
Zheng WQ, Pang C, Long Y. Observation of therapeutic effect of garlicin capsule on liver fibrosis in children with chronic hepatitis B. J Guangdong Med College 2004; (03): 251-2.
[http://dx.doi.org/10.3969/j.issn.1005-4057.2004.03.022]
[90]
Yan N. Observation of the therapeutic effect of compound glycyrrhizin injection on chronic hepatitis B. China Pharm 2004; 15(6): 355-6.
[http://dx.doi.org/10.3969/j.issn.1001-0408.2004.06.019]
[91]
Ye XS. Clinical observation on 32 cases of chronic hepatitis B treated with Cassilai. Mod J IntegrTrad Chin West Med 2004; (07): 862.
[http://dx.doi.org/10.3969/j.issn.1008-8849.2004.07.012]
[92]
Huang YQ. The effect of kurorinone on the serum level of TNF - α and IL - 6 in patients with chronic hepatitis B. J. Chin Phys 2004; (10): 1322-3.
[http://dx.doi.org/10.3760/cma.j.issn.1008-1372.2004.10.012]
[93]
Chen QC. Observation on the clinical effect of Ganlixin injection on chronic hepatitis B. J Zhangjiakou Med College 2004; (02): 33-4.
[http://dx.doi.org/10.3969/j.issn.2095-1396.2004.02.016]
[94]
Jiang SX. The effect of diammonium glycyrrhizinate on alpha-fetoprotein of patients with chronic hepatitis B. Acta Medicinae Sinica 2001; (6): 784-5.
[http://dx.doi.org/10.3969/j.issn.1008-2409.2001.06.009]
[95]
Yang XY. Clinical observation on 44 cases of chronic hepatitis B treated with hububutin combined with garlicin. Guangdong Yixue 1998; (5): 391-2.
[96]
European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67(2): 370-98.
[http://dx.doi.org/10.1016/j.jhep.2017.03.021] [PMID: 28427875]
[97]
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update. Hepatol Int 2016; 10(1): 1-98.
[http://dx.doi.org/10.1007/s12072-015-9675-4] [PMID: 26563120]
[98]
Zhang C, Yang D. From guideline to guidance: Update on prevention, diagnosis and treatment of chronic Hepatitis B: AASLD 2018 Hepatitis B guidance. Zhongguo Shiyong Neike Zazhi 2018.
[http://dx.doi.org/10.19538/j.nk2018060114]
[99]
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4): 1560-99.
[http://dx.doi.org/10.1002/hep.29800] [PMID: 29405329]
[100]
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295(1): 65-73.
[http://dx.doi.org/10.1001/jama.295.1.65] [PMID: 16391218]
[101]
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130(3): 678-86.
[http://dx.doi.org/10.1053/j.gastro.2005.11.016] [PMID: 16530509]
[102]
Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway. World J Gastroenterol 2012; 18(7): 679-84.
[http://dx.doi.org/10.3748/wjg.v18.i7.679] [PMID: 22363140]
[103]
Chen Y. Protective effect of diammonium glycyrrhizinate phosphatidylcholine complex on D-galactosamine hydrochloride-induced acute liver injury in rats. J Clin Hepatol 2006; 9(3): 133-6.
[http://dx.doi.org/10.3969/j.issn.1672-5069.2006.03.002]
[104]
Wang LQ. Application and evaluation of blind method in randomize controlled trials of Chinese medicine. J Tradit Chin Med 2014; (01): 28-33.
[http://dx.doi.org/10.13288/j.11-2166/r.2014.01.008]
[105]
Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Clin Oral Investig 2001; 285(15): 1987-91.
[http://dx.doi.org/10.1016/j.explore.2004.11.001] [PMID: 16791967]

Rights & Permissions Print Cite
Article Metrics
23
1
© 2024 Bentham Science Publishers | Privacy Policy